Results 41 to 50 of about 80,955 (206)

PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade. [PDF]

PLoS ONE, 2013
BACKGROUND: Novel immunosuppressive therapy facilitates long term allograft survival, but acute tubular necrosis and ischemia-reperfusion during transplantation can compromise allograft function.
Karoly Kalmar-Nagy, Peter Degrell, Aliz Szabo, Katalin Sumegi, Istvan Wittmann, Ferenc Gallyas, Balazs Sumegi   +6 more
doaj   +1 more source

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research, 2019
Background The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti   +9 more
doaj   +1 more source

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment

Cancer Cell International, 2023
Background Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder defined by cytopenia and is associated with an increased risk of transformation to acute myeloid leukemia (AML).
Seiichi Okabe, Yuko Tanaka, Mitsuru Moriyama, Akihiko Gotoh   +3 more
doaj   +1 more source

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

Cell Reports, 2023
Summary: Ovarian high-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer with limited therapeutic options and a poor prognosis. In recent years, poly-ADP ribose polymerase (PARP) inhibitors have demonstrated significant clinical ...
Yuewei Xu, Sarah Spear, Yurui Ma, Marc P. Lorentzen, Michael Gruet, Flora McKinney, Yitao Xu, Chiharu Wickremesinghe, Madelen R. Shepherd, Iain McNeish, Hector C. Keun, Anke Nijhuis   +11 more
doaj   +1 more source

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil

, 2023
To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March
Angelica Nogueira-Rodrigues, Michelle Samora Almeida, Rachel Cossetti, Karime Kalil, Marcela Crosara, Aknar FC Calabrich, Daniele Xavier Assad, Ana Carolina Leite, Andreia C Melo, Carla Rameri de Azevedo, Andrea PG Guimarães, Alessandra Menezes Morelle, Eduardo Cronemberger, Rodrigo Guindalini, Eduardo Paulino, Graziela Dal-Molin, Daniela de Freitas, João Soares Nunes, Poliana Signorini, Fernando C Maluf   +19 more
core   +1 more source

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Cell Reports, 2019
Summary: Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment.
Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey E. Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers   +13 more
doaj   +1 more source

Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter

, 2012
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, J.W., Champion, S., Babich, John W, Mairs, Robert J, Gaze, Mark N, Tesson, Mathias, McCluskey, Anthony G, Champion, Sue, Mairs, R.J., McCluskey, A.G., Gaze, M.N., Pimlott, S.L., Boyd, Marie, Tesson, M., Boyd, M., Pimlott, Sally L   +15 more
core   +1 more source

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer

Asian Journal of Andrology, 2014
Recent phase I studies have reported single-agent activities of poly (ADP-ribose) polymerase (PARP) inhibitor in sporadic and in BRCA-mutant prostate cancers.
Jingsong Zhang
doaj   +1 more source

Genotoxic effects of 1-nitropyrene in macrophages are mediated through a p53-dependent pathway involving cytochrome c release, caspase activation, and PARP-1 cleavage

Ecotoxicology and Environmental Safety, 2021
Genotoxic stress from environmental pollutants plays a critical role in cytotoxicity. The most abundant nitro-polycyclic aromatic hydrocarbon in environmental pollutants, 1-nitropyrene (1-NP), is generated during fossil fuel, diesel, and biomass ...
Sheng-Wen Wu, Chun-Hung Su, Yung-Chuan Ho, Rosa Huang-Liu, Ching-Chi Tseng, Yun-Wei Chiang, Kun-Lin Yeh, Shiuan-Shinn Lee, Wen-Ying Chen, Chun-Jung Chen, Yi-Ching Li, Chien-Ying Lee, Yu-Hsiang Kuan   +12 more
doaj   +1 more source

PARP Inhibitor Resistance - What Is Beyond BRCA1 or BRCA2 Restoration?

, 2015
Nearly 10 years ago the usefulness of poly(ADP-ribose) polymerase (PARP) inhibitors to kill BRCA1 or BRCA2-deficient cells was reported, and this finding has served as a prime example of the concept of synthetic lethality in the context of anticancer ...
Xu, Guotai, Guotai Xu, Jonkers, Jos, Rottenberg, Sven, Jos Jonkers, Sven Rottenberg   +5 more
core   +1 more source